Purpose: We investigate the value of pretreatment serologic antienzyme rate (AER) of Epstein-Barr virus (EBV) DNase-specific neutralizing antibody complementing TNM staging in prognostication of nasopharyngeal carcinoma (NPC).
Patients And Methods: Pretreatment serum samples from 1,303 patients with untreated NPC were collected and examined for AER. After a 10-year follow-up period, the prognoses of the patients, classified by their clinical stage with AER, were assessed by multivariate analysis. Of the 1,303 patients, 600 patients were randomly assigned to a training set to generate an AER cutoff point by receiver operating characteristic (ROC) curve analysis. AER levels were then analyzed with overall survival (OS), progression-free survival (PFS), local failure-free survival (LFFS), and distant metastasis-free survival (DMFS) in a testing set (703 patients). Another independent cohort of 464 patients was studied in a validating set.
Results: In the training set, the ROC analysis-generated AER cutoff point for OS was 58.0%, which was used as the cutoff point in the testing set. The subset of low AER levels predicted a significant survival advantage over the subset of high AER levels for OS, PFS, LFFS, and DMFS in the testing set. Moreover, two distinguished subgroups were segregated by an AER level of 58.0% within each clinical stage comparing prognostication of OS, PFS, LFFS, and DMFS. Importantly, AER level was revealed as the only significant independent prognostic factor for death, recurrence, and distant metastasis in the validating set.
Conclusion: Pretreatment serologic AER of EBV DNase-specific neutralizing antibody serves as an independent prognostic marker complementing TNM stage in NPC. Supplementing pretreatment AER with TNM staging leads to more accurate risk definition in patient subgroups.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1200/JCO.2009.25.6552 | DOI Listing |
Cancer Med
August 2019
School of Public Health, Sun Yat-sen University, Guangzhou, China.
Epstein-Barr virus (EBV) reactivation, reflected by aberrantly increased levels of various serological antibodies, has been suggested to be an early indicator of nasopharyngeal carcinoma (NPC) onset and progression. We have previously suggested that certain lifestyle and dietary factors were associated with elevated serological levels of the antibody against various EBV antigens namely VCA, Zta, EBNA1, and oral EBV DNA loads among healthy population. It remains unclear whether these potential environmental factors would also influence EBV serological antibodies in NPC patients.
View Article and Find Full Text PDFHead Neck
May 2015
Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China; Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China.
Background: The purpose of this analysis was to create a prognostic score model for newly diagnosed nasopharyngeal carcinoma (NPC) which has not been created before.
Methods: We retrospectively reviewed the medical records of 419 patients with newly diagnosed, nondisseminated, and biopsy proven NPC.
Results: Independent prognostic factors included age >45, stage III/IV, antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody (AER) >58%, and absolute neutrophil count (ANC) >4.
J Clin Oncol
December 2010
State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, 651 Dongfeng Rd East, Guangzhou 510060, China.
Purpose: We investigate the value of pretreatment serologic antienzyme rate (AER) of Epstein-Barr virus (EBV) DNase-specific neutralizing antibody complementing TNM staging in prognostication of nasopharyngeal carcinoma (NPC).
Patients And Methods: Pretreatment serum samples from 1,303 patients with untreated NPC were collected and examined for AER. After a 10-year follow-up period, the prognoses of the patients, classified by their clinical stage with AER, were assessed by multivariate analysis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!